Viva In Vitro is developing Viva Sepscare®, an immunology-based diagnostic prototype to detect NLRP3 inflammasome activation and rapidly stratify sepsis patients. The company plans to extend clinical validation of the device to multiple sclerosis and other inflammatory diseases. Its near-term priorities are completing the alpha prototype, expanding clinical validation and advancing regulatory processes to enable commercial prospecting—particularly with pharmaceutical partners—and internationalization. The team is based at the Parque Científico de Murcia and emphasizes product engineering and stronger corporate governance as it scales. Leadership cited includes director Toni Vilaplana, executive chairman Joaquín Gómez Moya and founder Dr. Pablo Pelegrín, who coordinates the scientific advisory committee. Financially, Viva In Vitro has attracted sustained investor and institutional support across three consecutive rounds completed in under 36 months. Viva In Vitro Diagnostics is a spin‑off from the Instituto Murciano de Investigación Biomédica (IMIB) constituted in September 2021. The company is developing technology to stratify and predict outcomes for patients with abdominal sepsis. Its plan is to commercialize that technology by creating a compact device that uses disposable cartridges. The initial product effort focuses on early‑hours sepsis mechanisms studied by the founding research group. The company closed a seed round to fund development and to strengthen applications for public support, including the European Innovation Council. No revenue or user metrics are reported in the article.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2024